SEB har mod betaling udarbejdet denne analyse af Fluoguide:
FluoGuide announced that it has acquired exclusive rights to a patent to use FG001 for photothermal therapy, an extension of photodynamic therapy that kills cancer cells with heat. The press release referenced strong preclinical data, and the application is important to justify our drug cost assumptions. The patent extends FluoGuide’s IP to 2039 from 2034, materially extending peak sales and cash flows.
Photothermal therapy is an exciting application for FG001
We raised the prospect of using FG001 for photodynamic therapy in our initiation report, noting that it could enable FG001 to kill residual cancer cells at the tumour margin, while sparing healthy tissue, taking advantage of the deep tissue penetration of near-infrared light. The difference here is that the newly announced method would use light-induced heat production, rather than free radicals, to kill cancer cells. There is a theoretical rationale for arguing that this method would produce superior outcomes, but in our view, it is largely academic, and the main thing is that the killing of residual cancer cells by FG001 would improve surgical outcomes versus fluorescence-guided surgery alone.
Generalt om Commissioned Research: Bemærk, at man bør se bort fra eventuelle kursestimater i såkaldt commissioned research, og den underliggende analyse skal også tolkes med forsigtighed, da negative aspekter ikke nødvendigvis fremhæves.
